These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2883156)

  • 1. Lysozyme and complement-dependent lysis of Entamoeba histolytica. Inhibition by leupeptin.
    Mogyoros M; Fishelson Z; Gitler C
    Isr J Med Sci; 1986 Dec; 22(12):918-20. PubMed ID: 2883156
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of the alternative complement pathway by various axenic strains of Entamoeba histolytica].
    Capin NR; Capin R; Zamacona G; Ortiz-Ortiz L
    Arch Invest Med (Mex); 1978; 9 Suppl 1():291-6. PubMed ID: 211963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica.
    Reed SL; Curd JG; Gigli I; Gillin FD; Braude AI
    J Immunol; 1986 Mar; 136(6):2265-70. PubMed ID: 2869084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of pathogenic and nonpathogenic Entamoeba histolytica with human complement.
    Reed SL; Gault M; Gillin FD; Gigli I; Braude AI; Curd JG; Sargeaunt PG
    Arch Invest Med (Mex); 1987; 18(2):141-9. PubMed ID: 2889433
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-surface antibodies to Entamoeba histolytica and their role in complement lysis.
    Trissl D; Müller R; Ries R; Rathmann M
    Arch Invest Med (Mex); 1986; 17 Suppl 1():203-8. PubMed ID: 2884957
    [No Abstract]   [Full Text] [Related]  

  • 6. Virulence of Entamoeba histolytica correlates with the capacity to develop complement resistance.
    Mogyoros M; Calef E; Gitler C
    Isr J Med Sci; 1986 Dec; 22(12):915-7. PubMed ID: 2883155
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of the alternative and classical complement pathways by Entamoeba histolytica.
    Calderon J; Schreiber RD
    Infect Immun; 1985 Nov; 50(2):560-5. PubMed ID: 2865212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between Entamoeba histolytica and complement.
    Huldt G; Davies P; Allison AC; Schorlemmer HU
    Nature; 1979 Jan; 277(5693):214-6. PubMed ID: 233113
    [No Abstract]   [Full Text] [Related]  

  • 9. Loss of susceptibility to complement lysis in Entamoeba histolytica HM1 by treatment with human serum.
    Calderon J; Tovar R
    Immunology; 1986 Jul; 58(3):467-71. PubMed ID: 2874111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin.
    Kaneko I; Fearon DT; Austen KF
    J Immunol; 1980 Mar; 124(3):1194-8. PubMed ID: 6898640
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel anti-inflammatory activity of lysozyme: modulation of serum complement activation.
    Ogundele MO
    Mediators Inflamm; 1998; 7(5):363-5. PubMed ID: 9883972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism of acquired resistance to complement-mediated lysis by Entamoeba histolytica.
    Gutiérrez-Kobeh L; Cabrera N; Pérez-Montfort R
    J Parasitol; 1997 Apr; 83(2):234-41. PubMed ID: 9105303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis.
    Hamelmann C; Foerster B; Burchard GD; Horstmann RD
    Parasite Immunol; 1992 Jan; 14(1):23-35. PubMed ID: 1557228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of susceptibility to antibody and complement mediated lysis in E. histolytica.
    Calderon J; Tovar-Gallegos R
    Arch Invest Med (Mex); 1980; 11(1 Suppl):241-4. PubMed ID: 6258517
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternative pathway complement activation induces reductions in effective hepatic blood flow.
    Schirmer WJ; Schirmer JM; Naff GB; Fry DE
    Curr Surg; 1987; 44(4):304-8. PubMed ID: 3665580
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
    Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
    J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
    Czop JK; Austen KF
    J Immunol; 1985 Nov; 135(5):3388-93. PubMed ID: 4045195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175.
    Miyamoto Y; Hirose H; Matsuda H; Nakano S; Ohtani M; Kaneko M; Nishigaki K; Nomura F; Kitamura H; Kawashima Y
    Trans Am Soc Artif Intern Organs; 1985; 31():508-11. PubMed ID: 3837498
    [No Abstract]   [Full Text] [Related]  

  • 19. Complement resistance of pathogenic Entamoeba histolytica mediated by trypsin-sensitive surface component(s).
    Hamelmann C; Urban B; Foerster B; Horstmann RD
    Infect Immun; 1993 May; 61(5):1636-40. PubMed ID: 8478051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alternative complement activation pathway. Its mechanism, importance and quantitative determination].
    Gancevici GG; Popescu C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):209-21. PubMed ID: 6390651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.